Blog

  • Arsenal’s stance over Thomas Partey feels morally indefensible

    Arsenal’s stance over Thomas Partey feels morally indefensible

    This is an updated version of an article first published in July 2022.


    Three years ago, I wrote a column on the Premier League footballer we can now name as former Arsenal midfielder Thomas Partey being arrested on suspicion of rape.

    At that time, The Athletic could not name him. That has changed now he has been charged with five counts of rape and one of sexual assault, allegations which relate to three separate women who reported incidents which took place between 2021 and 2022 and which he denies.

    Partey has been under investigation since February 2022 and was first arrested in July that same year. The piece I wrote, published in July 2022, detailed why I felt the (then unnamed) club’s decision not to suspend him while he was being investigated over such serious allegations sent the wrong message to women.

    In the period since then he has been arrested, questioned by police and bailed seven times, all while he was helping Arsenal come desperately close to winning the Premier League title. He also played for Ghana at the 2022 World Cup.

    Last season he made a total of 52 appearances for Arsenal in all competitions. Despite his contract at the club expiring on June 30, his image was still present on the official Arsenal website on Friday morning, only being removed later in the afternoon following the news that he had been charged.

    While the primary concern here is for the alleged victims, the optics of today’s news could hardly be worse for Arsenal.

    Their decision to keep on playing him, coupled with the vocal support offered by manager Mikel Arteta — who described how happy he was for Partey after he scored the opening goal in Arsenal’s 3-1 win over Tottenham in October 2022 (“for what he’s been through and the injuries… I’m so happy for him, he deserves it”) — already left them open to criticism.


    Mikel Arteta regularly picked Thomas Partey (Justin Tallis/AFP via Getty Images)

    Now, that is compounded by the timing of the Crown Prosecution Service’s decision to charge Partey just days after the expiry of his Arsenal contract.

    Whether the club knew this development was coming or not, they are now facing difficult questions over the way they have handled this situation. And the brief statement they issued last night — “The player’s contract ended on June 30. Due to ongoing legal proceedings the club is unable to comment on the case” — does nothing to answer them.

    Back in July 2022, the club issued a lengthier statement about their decision to keep playing Partey. It read: “We’ve confirmed that the player denies the allegations and is on police bail… There have been no charges laid and the player can fulfil his professional commitments.”

    At the time, I was conflicted, weighing what appeared to be a reasonable legal position, particularly in light of the player’s denials, against the severity of the allegations and the fact that sport occupies such a powerful place in society.

    There is a part of my brain that still tries to rationalise Arsenal’s actions. Had they suspended him for all that time only for him to then be cleared — as may, of course, yet happen — would that have been fair, given the brevity of a professional footballer’s career?

    Might they also have been concerned about the potential legal ramifications? Last year, former Manchester City player Benjamin Mendy won his claim against the club over unpaid wages while he was facing criminal charges following allegations of sex offences. He was subsequently cleared of all charges.

    But morally and emotionally, I find it difficult to accept how the club has approached this situation.

    Even if you make the argument for Arsenal being wary of the legal ramifications of suspending Partey, what then can be made of their apparent desire to extend his contract beyond this summer? In April this year, The Athletic reported that the club had entered talks with the midfielder about a new deal. Given the ongoing investigation and allegations against him, this raises yet more uncomfortable questions.

    Arsenal have long led the way in championing the women’s game, and have traditionally been held up as a football club that “does things the right way”. Yet for the past three years, they have acted in a manner that raises so many questions about the moral compass of the game and how it really views allegations of sexual assault towards women.

    They have acted in a way that has left many fans feeling uncomfortable and conflicted as they supported their team through the highs and lows of the seasons.

    They have acted in a way that simply has not felt right.


    On the eve of the 2022 Women’s European Championship, I spoke to UK TV presenter Gabby Logan about her relationship with the game and she said something that came to mind when I read Arsenal’s initial statement three years ago.

    Logan said: “Football reflects so many attitudes in society. Sometimes I think it reflects where we are as a civilisation in terms of attitudes and how important subjects like racism and homophobia are handled. If football treats it seriously, then it sends a really strong message.”

    What message does it send when a club basically says it’s ‘business as usual’ after allegations of rape are made? Does it say they are treating them with the seriousness they deserve? Does it send a strong message to their players, staff and fans about how they feel such allegations should be acted upon?


    Partey left Arsenal on June 30 when his contract expired (Justin Setterfield/Getty Images)

    Female players and members of staff at the club — including, potentially, in the medical team — will undoubtedly have to be around and interact with the player in question, as will others who no doubt will all know about the claims against him.

    I ask myself how I would feel in their situation. The answer is potentially uncomfortable.

    The club’s statement in 2022 said they take their “commitments and responsibilities seriously”, but their actions regarding the player we now can name as Partey suggested they did not treat the allegations made against him with the same level of seriousness.

    There have been other examples of clubs suspending players and members of staff after serious allegations. Mason Greenwood was suspended by Manchester United after being arrested in January 2022 on suspicion of attempted rape and assault, with charges subsequently being dropped. Another Premier League club suspended a player in 2021 after he was arrested on suspicion of committing child sex offences. That case was also dropped.

    Those two players’ club suspensions did not mean their employers were slapping a “guilty” verdict on them, but it did mean they were being seen as treating the allegations with the respect that they deserved. That they understood the implications and potential impact on the alleged victims and those around the accused. That they recognised the message their reaction sends to wider society.

    It should also be noted that Arsenal are not alone in their decision not to suspend a player facing sex offence allegations.

    Yves Bissouma, then of Brighton and now of Tottenham, wasn’t suspended when he was arrested under suspicion of sexual assault in Brighton in October 2021 (Bissouma was cleared of the allegation in June 2022).


    Yves Bissouma played on for Brighton despite facing sexual assault allegations. He was later cleared (Clive Brunskill/Getty Images)

    Nor was Mendy suspended after allegations of nine sexual offences against six women, until he was charged by police.

    These examples only serve to reinforce the flimsy message that football — and, specifically in the Partey case, Arsenal — have sent about its attitude towards allegations of rape and sexual assault. And they do little to quash the idea that the bar for players getting suspended is placed far too high.

    It’s not hard to imagine what would happen to a member of a club’s backroom staff if they were facing the same allegations. So, why is it different for a player?

    There’s one answer that immediately springs to mind, and it’s not one that should even be in the reckoning when it comes to such serious claims.

    Violence towards women and girls is happening in scary numbers. It’s an issue that the UK government has promised to tackle, but it’s also one that should force us to examine our own attitudes and actions when allegations are made, and the messages they are sending to those around us.

    And that includes football clubs.

    (Top photo: Stefan Koops/EYE4images/NurPhoto via Getty Images)


    Comments have been disabled on this story to avoid potential breaches of UK law. For more information on why The Athletic occasionally disables comments on stories, please click here.

    Continue Reading

  • My cultural awakening: a Marina Abramović show helped me to stop hating my abusive father | Marina Abramović

    My cultural awakening: a Marina Abramović show helped me to stop hating my abusive father | Marina Abramović

    On an unseasonably warm day in October 2023, I arrived, ahead of the queues, at London’s Southbank Centre for a conceptual art takeover by the world-famous Marina Abramović Institute.

    I had recently read Marina’s memoir Walk Through Walls, which had resonated. So, when I’d seen the event advertised – hours-long performances by artists she’d invited, curated and introduced by Marina – I bought a £60 ticket and waited for my time slot to enter the Queen Elizabeth Hall. I hadn’t seen performance art before, and this was due to include her well-known work The Artist Is Present with an artist sitting, static and silent, in a chair all day, as Marina once did for an accumulated 736 hours and 30 minutes at the Museum of Modern Art. I felt certain that it would affect me, I just wasn’t sure how.

    It came at an interesting time in my life. I was raised in a fundamentalist Christian family, the daughter of a priest who was physically abusive. I’d been in therapy for years, but my experiences still affected me and I’d recently cut contact with my father with my family. So, when I entered the first room at the Southbank where Marina was to spoke and introduce around a dozen artists, I was still coming to terms with this new way of dealing with my past.

    I was immediately drawn to one of the artists, a man from Myanmar who was to perform the chair piece with a cloth sack over his head. We heard how he’d been part of an organisation in Myanmar that opposed violence and therefore risked death if he was publicly identified. I was moved by what he was risking for his art. I also knew it was a hard piece; Marina wasn’t going to give it to just anyone.

    As people moved between performers, I saw him, seated in the atrium, with a large crowd; I waited for a quieter moment to return. When I finally stood before him, I was overcome. I felt an urge to sit down in front of him and didn’t care what others thought. I was compelled to do it for myself. I can’t say how long I sat there, maybe an hour. In that time, I rewrote my definition of “strength”. I used to think my father’s aggression made him strong but now I saw someone using his muscular arms and legs to be still, for peaceful protest. I imagined the loss he must have experienced in war and the mental strength to sit there. I thought of what I’d read in Marina’s book; how pain set in three hours into sitting still.

    I cried: the good tears, where you let part of your past go. It felt cleansing. When I left, I felt lighter. I decided that this would be my father figure now: this person who had strength but did not hurt me, who had reasons to be aggressive but did not direct his anger towards a six-year-old whispering in her brother’s ear or disturbing his preaching, as my father had.

    It unlocked something in me. It gave me a positive male figure to replace what had gone before and helped me not to hate my father or men. It also unblocked the creativity that had laid dormant within me, an artistic side that had reminded me too much of my father’s similar creative charisma. I started drawing: comic-books and illustrations.

    I’m an atheist but I believe there are spiritual moments you can choose to embrace: this, for me, was one. I think of it often. I even have the poster from the takeover in my toilet, serving as a daily reminder. I’m 41 and throughout life I’ve learned to expect the unexpected. Usually, when I go to see art it’s to learn something new, and this was a big one. This changed me as a woman, as a soul, an immigrant, a creative, a child. That man gave himself to us as an artist and I accepted his gift.

    Share your experience

    You can tell us how a cultural moment has prompted you to make a major life change by filling in the form below or emailing us on cultural.awakening@theguardian.com.

    Your responses, which can be anonymous, are secure as the form is encrypted and only the Guardian has access to your contributions. We will only use the data you provide us for the purpose of the feature and we will delete any personal data when we no longer require it for this purpose. For true anonymity please use our SecureDrop service instead.

    Continue Reading

  • How to manage your money in turbulent times, from savings to mortgages | Money

    How to manage your money in turbulent times, from savings to mortgages | Money

    It is understandable to be worried about your finances. The world seems to be lurching from one political crisis to the next, and each one has an impact on stock markets and prices.

    A recent survey found UK consumers are worried about a slowing economy, possible tax increases in the next budget and rising food costs. We asked experts how you should manage your money in an uncertain world.

    Investments

    Stock markets around the world, especially in the US, were in flux earlier this year over Donald Trump’s tariff plans. Things have settled down now but it is impossible to predict what shocks may be around the corner.

    If you hold stocks and shares – in an Isa or pension, perhaps – you may have been nervously checking their value. UK fund managers have been increasing their holdings in US companies over recent years, largely fuelled by the boom in tech stocks, so big moves over there have an impact here.

    However, experts say the most important thing to do is to not sell up out of panic. The analyst Dan Coatsworth of the financial advisers AJ Bell says: “The worst thing people can do is to see troubling things in the news and then suddenly try to shift around their portfolio.” Markets have recovered in the past, he says, so patience is key.

    Gold has tripled in price over the past decade. Photograph: Denys Rudyi/Alamy

    Where this advice may differ is if you need your money for something in less than five years – such as a wedding, university fees or a house purchase. Then you should look at how much risk you are taking, he says.

    Andrew Oxlade, an investment director at the fund management company Fidelity International, says this could mean switching some of your money away from the markets and into bonds. Bonds are issued by a corporation or country – the investor loans it money in exchange for a fixed rate of interest.

    They are typically bought through a fund. Many investment management companies offer funds that have a split between equities and bonds, such as Vanguard’s Lifestrategy 80%.

    Gold, an investment that is often seen as a safe bet during times of crisis, has tripled in price over the past decade, and many investors now hold a small amount in their portfolios, Oxlade says, after years of poor performance. Investing does not have to mean buying bars or coins – Fidelity says the most direct way for most is through an exchange traded fund that tracks the price of gold.

    Mortgages

    Interest rates in the UK can be affected by what goes on globally. The Bank of England is tasked with keeping inflation down. Before the war in Ukraine started, it had begun to put up rates, and as prices increased, it continued, raising them from 0.25% at the start of 2022 to 5.25% by August 2023, before holding them there for another year.

    The Bank has been reducing rates and is expected to make more cuts later this year, but the question is when. If you are planning to take out a new mortgage – either to buy a home or as a remortgage – you face a decision about whether to fix for the short or long term, choose a tracker or even to go on a bank’s standard variable rate (SVR).

    Currently, the best-priced two- and five-year fixed deals have a rate of just below 4%.

    Nick Mendes of the brokers John Charcol says lenders are reducing rates at present largely because of falling swap rates, a key factor in how mortgages are priced. Swap rates reflect what the money markets expect to happen to interest rates in future.

    “Fixed mortgage rates are more influenced by swap rates than the base rate itself, which means they are shaped by what markets think might happen in the future rather than what is happening today,” he says.

    If you want to take out a mortgage you face a decision about whether to fix for the short or long term, choose a tracker or go on a bank’s SVR. Photograph: Ian Nolan/Getty Images/Image Source

    Going on to a lender’s SVR in the hope that fixed rates will improve later in the year is a risky strategy as the rates are high, at about 6.5%, and can change at any time and increase your monthly repayments.

    Tracker mortgages are also worth considering, Mendes says. These are linked to the Bank base rate. “They tend to start lower than SVRs and often come without early repayment charges, which means borrowers can move on to a fixed deal later,” he says.

    Mendes says people who are remortgaging should not “sit back and wait. Most lenders allow you to secure a new deal up to six months in advance, which is a smart way to hedge your bets,” he says. “You can lock in a deal now as a safety net and still switch to something better if rates improve before the new deal begins.”

    For new buyers, Mendes says they should base decisions on what is affordable now rather than making assumptions about what may or may not happen in the future. “The last position anyone wants to be in is having overstretched themselves on the assumption that they will be able to refinance on to something cheaper at the end of their fixed-rate period,” he adds.

    You are not tied to a rate until completion, so you should be able to switch if a better deal comes along.

    Savings

    Savings rates could fall even before the Bank reduces the base rate, says Rachel Springall of the financial information site Moneyfacts, as account providers may decide that they have enough deposits for a certain product. “If the whole market starts moving in one direction, you’ll find that other peers will do the same because they don’t want to put themselves too high up [in best buy tables],” she says.

    Until then, easy access and fixed-term rates are competitive, Springall says.

    The best rates this week for fixed one-year and two-year bonds are from Cynergy Bank (4.55% for the one-year and 4.45% for the two-year), while an easy access account from Chase offers 5%, although this includes a 12-month bonus and is a variable rate, so it could go down.

    There have been increases in the interest paid on fixed-rate bonds in recent weeks, she says.

    Anna Bowes of the financial advisers The Private Office says “now is a really good time for a saver who has not been paying attention to their savings” as there is good competition in the market.

    If you have money in a variable-rate account it may be a good time to move it to a fixed rate.

    Pensions

    The tumultuous times that stock markets have been having since the start of the year will have had a direct effect on many people in the UK through their pensions. Often funds are heavily invested in US stocks, so the ups and downs there could be affecting your retirement saving.

    It is understandable if you are considering shifting money in your pension into other safer options such as bonds, says Helen Morrissey, the head of retirement analysis at the financial advice company Hargreaves Lansdown. However, unless you are cashing in your pension within the next five years, you should avoid reactions based on the international turmoil, she says.

    The tumultuous times that stock markets have been having this year will affect many people in the UK through their pensions. Photograph: Alamy/PA

    “Over the course of your saving journey, you will hit several periods of market volatility and it’s important to keep in mind that markets do recover over time,” she says. “Making kneejerk reactions such as changing investment strategy has the potential to lock in losses as you miss out when markets do recover.”

    Workplace pensions are often invested in “lifestyling” funds, which reduce the amount of risk as the holder gets older by shifting from equities to bonds. So if you are approaching retirement this may be happening automatically.

    If your fund has been hit by turbulence in the markets and you intend on retiring soon, Morrissey says that you may want to start to take a lower amount out from your fund than you had planned in order to allow the rest to recover from any losses caused by market turbulence.

    “We suggest that people in [income] drawdown keep between one and three years’ worth of essential expenditure [from their savings] in an easy access account that they can use to supplement their income during times of turbulence,” she adds.

    Another option, on retirement, is to invest some or all of your fund in an annuity, where returns are close to all-time highs. Annuities convert a lump sum from your pension into a regular guaranteed income for the rest of your life or a fixed term. A healthy 65-year-old can now get an annuity rate of 7.72% on average, according to the pension provider Standard Life – that means that for every £100,000 invested, they would get an annual income of £7,720.

    Energy bills

    About 21 million households will see their bills decrease after the price cap was reduced this week. For a household with typical usage, the cap has dropped by £129, to £1,720 a year. The good news may not last too long, however, as there are predictions of increases in October.

    After the recent conflict between Iran and Israel, oil prices went up because of concerns that supplies could be affected by threats of a blockade of the strait of Hormuz. Prices later reduced after a ceasefire deal was agreed.

    The energy price cap has dropped, but that may not be for long. Photograph: Christopher Thomond/The Guardian

    Will Owen of the price comparison website Uswitch says the volatility of the international economy has led to uncertainty. “We are now seeing predictions from various organisations and energy suppliers that the price cap from October onwards will probably go up,” he says.

    To protect yourself against a rise you could considered a fixed-rate tariff – with these each unit of energy and the standing charges are set for a certain length of time.

    The MoneySavingExpert site advises that you are “very likely” to save if you can find a fixed-rate deal priced at least 5% below the current price cap, which is predicted to fluctuate.

    The current best deals are a 12-month fix from E.ON Next that is 8.8% below the cap, another from Outfox Energy that is 8.1% less and then a fix from EDF Energy that is 7.2% less, according to the site.

    Continue Reading

  • Steve Coogan accuses Labour of paving way for Reform UK | Steve Coogan

    Steve Coogan accuses Labour of paving way for Reform UK | Steve Coogan

    Steve Coogan has accused Keir Starmer’s Labour government of a “derogation of all the principles they were supposed to represent” and said they were paving the way for the “racist clowns” of Reform UK.

    The actor, comedian and producer said the party he had long supported was now for people “inside the M25” and described the prime minister’s first year in power as underwhelming.

    “I knew before the election he was going to be disappointing. He hasn’t disappointed me in how disappointing he’s been,” he said.

    Coogan spoke to the Guardian ahead of an address to the annual Co-op Congress in Rochdale, Greater Manchester, where he called for locally led grassroots movements to assemble across Britain and take back control from “multinational institutions and billionaires”.

    The Bafta-winning actor, best known for his Alan Partridge persona, has backed Labour in several recent general elections but switched his support last year to the Green party.

    Coogan, 59, said he “agreed wholeheartedly” with the statement released by former Labour MP Zarah Sultana on Thursday night, when she announced she was quitting the party to co-lead a left-wing alternative with Jeremy Corbyn.

    Sultana said Britain’s two-party system “offers nothing but managed decline and broken promises” and that Labour had “completely failed to improve people’s lives”.

    Coogan said: “Everything she said in her statement I agree wholeheartedly. I wish I’d said it myself.” However, he added that he was “reserving judgment” as to whether to support the new party at future elections if they field candidates.

    The Philomena star said he did not blame working people for voting for Nigel Farage’s Reform UK.

    “The success of Reform, I lay squarely at the feet of the neoliberal consensus, which has let down working people for the last 40 years and they’re fed up,” he said. “It doesn’t matter who they vote for, nothing changes for them.

    “Keir Starmer and the Labour government have leant into supporting a broken system. Their modus operandi is to mitigate the worst excesses of a broken system and all that is is managed decline. What they’re doing is putting Band-Aids on the gash in the side of the Titanic.”

    In his most strongly worded attack on Labour yet, Coogan described the party’s priorities in the last year as “a derogation of all the principles they were supposed to represent”.

    “We have a Labour government and it’s no different from a Conservative government in neglecting ordinary people,” he added.

    “I think Labour governs for people inside the M25 that’s who they’re preoccupied with, and gesture politics. Every decision that comes from central government these days to me looks political and strategic and nothing to do with sincerity or any kind of firmly held ideological belief.”

    Without meaningful action to improve the lives of ordinary people, Coogan said, both Labour and the Conservatives would face electoral oblivion.

    “They’ll pave the way for the only alternative, which is a racist clown. Reform couldn’t organise a piss up in a brewery but if there’s no alternative you understand why working people will make that choice,” he said.

    Coogan spoke in Rochdale’s Grade I-listed town hall, which this weekend is hosting a congress of co-operative movements from across the world to mark this year’s UN-designated International Year of Co-operatives.

    The actor is a supporter of Middleton Co-operating, a community-led initiative based in his home town, just outside Manchester, which aims to provide locally run energy, banking, social care, housing and other schemes.

    He said the government’s focus on attracting investment to major cities had created a “doughnut of neglect” with poorer communities “ethnically cleansed”.

    “You look at Manchester, you look at Liverpool, and you go: ‘Wow, look at these shiny new buildings’ and everything looks clean, there’s no crisp bags flying about in the street,” he said.

    “The disenfranchised people who lived there before are not there any more. They’ve been ethnically cleansed. They’ve been booted out to the next poor area. So who’s benefiting?”

    Coogan urged Labour to breathe life back into towns by empowering grassroots groups to take over neglected buildings, using compulsory purchase orders for example.

    “It’s not just the fact that people are disempowered and feel like they have no autonomy. It’s compounded by the fact that these people, these multinationals, are enabled and supported by the government to keep their foot on the neck of working people,” he said.

    It was “perfectly understandable” for working people to vote for Farage’s Reform in large parts of England, where many voters feel disenfranchised, Coogan said.

    “But if any government wants to address that extremism, what they have to do is tackle the root cause,” he added.

    “The root cause is poverty and economic decline in the post-industrial landscape, especially in the north. If Labour addressed that problem, Reform would go away – all their support would dissipate.”

    Continue Reading

  • Trump says US will start talks with China on TikTok deal this week – Reuters

    1. Trump says US will start talks with China on TikTok deal this week  Reuters
    2. News Agency Reuter’s X Handle Withheld In India  ABP Live English
    3. Trump Grants Third Deadline Extension for TikTok Sale  NBC Palm Springs
    4. Donald Trump signals breakthrough in US-China TikTok deal  MSN
    5. Trump says the US ‘pretty much’ has a deal on TikTok  Dunya News

    Continue Reading

  • Boosting Hydroxyl Radical Generation with Nitrogen Vacancies Modified

    Boosting Hydroxyl Radical Generation with Nitrogen Vacancies Modified

    Introduction

    Oral squamous cell carcinoma (OSCC) is a major global health issue, with over 350,000 new diagnosed cases and a high mortality rate each year.1 Conventional surgical treatment based on removing primary lesions causes serious side effects, such as loss of facial function (chewing, swallowing, and speaking) and different levels of aesthetic change.2 In addition, the much higher levels of DNA-damage repair in cancer cells than in normal cells can easily cause tumor resistance during radiotherapy and chemotherapy.3

    Photodynamic therapy (PDT), with its advantages of light-controlled selectivity, minimal invasiveness, and low side effects, has garnered significant attention.4 FDA-approved photosensitizers, such as chlorin e6 (Ce6) and 5-aminolevulinic acid, have been used to treat superficial tumors.5,6 However, almost all solid cancers are characterized by hypoxia, and the hypoxic tumor microenvironment can reduce effectiveness of the two abovementioned agents.7 Other photosensitizers, such as MnO2 and Fe-MOF, can catalyze the production of highly toxic •OH with H2O2,8,9 inducing multiorganelle damage in tumors. While these can be modified for targeted •OH generation, the potential release of metal ions poses a threat to health.10,11 In the ongoing search for anticancer photocatalysts that can inflict oxygen-independent tumor damage, inhibit DNA-damage repair, and prevent organ damage from metal residues, researchers have set their sights on polymeric carbon nitride (PCN), a nanomaterial composed exclusively of carbon and nitrogen elements. Unfortunately, the PDT anticancer effect of pristine PCN is not satisfactory due to the limited •OH caused by surface inertness and severe carrier recombination.12

    In this study, nitrogen vacancy–modified PCN (NV-PCN) was synthesized to improve the cell accessibility of carbon nitride by increasing the content of –NH2 and provide more reactive sites for H2O2 reduction. As presented in Figure 1, NV-PCN leads to a synchronous explosion of •OH around the nuclei and mitochondria of Cal-27 cells under illumination, which synchronously leads to nucleus DNA damage (increased expression of double-strand break marker γH2AX) and mitochondrial dysfunction (decreased mitochondrial membrane potential [MMP]). Mitochondrial dysfunction triggers an ROS storm to intensify DNA damage, and the ATP energy chain is attenuated to inhibit DNA-damage repair (reduced expression of 53BP1 and GADD45A). Compared to Ce6, NV-PCN exhibits excellent anticancer performance in vitro and in vivo, opening up new avenues for carbon nitride-based cancer PDT.

    Figure 1 Schematic illustration of (a) the preparation process and (b) the therapeutic process of NV-PCN.

    Results and Discussion

    Material Characterization of NV-PCN

    The morphologies of pristine PCN and NV-PCN were observed by TEM. NV-PCN exhibited an irregular flaked structure with a diameter of approximately 100 nm (Figure 2a), half that of PCN (Figure S1). XRD and FTIR tests were conducted to reveal the crystal phase and surface functional groups. In Figure 2b, the pristine PCN exhibits two typical diffraction peaks at 13.0° and 27.4°, which are assigned to the periodic stacking of tri-s-triazine rings in plane (100) and graphitic layer (002), respectively.13 The XRD pattern of NV-PCN exclusively presents the diffraction peaks of the PCN component, revealing that the crystal structure of NV-PCN is similar to that of PCN. However, all peaks of NV-PCN weaken compared to PCN, suggesting a distorted structure and smaller dimensions of unit cells of NV-PCN than PCN.14 As shown in Figure 2c, PCN and NV-PCN possess similar FTIR spectra. Specifically, the peaks at 3500–3000, 1650–1245, and 810 cm−1, are attributable to the stretching vibrations of N–H group, stretching modes of tri-s-triazine rings in plane, and the out-of-plane bending mode of heptazine rings, respectively.15 This indicates that the basic structure of carbon nitride was preserved during the secondary roasting process.

    Figure 2 Characterization of as-prepared NV-PCN. (a) TEM image of NV-PCN. (b) XRD patterns, (c) FTIR spectra, and (d) N1s XPS signals of PCN and NV-PCN. (e) Structure diagram of NV-PCN. (f) UV-vis diffuse reflectance spectra. Inset: Tauc plots. (g) Band structures of PCN and NV-PCN. h) In situ DRIFT spectra of H2O2 on PCN and NV-PCN under illumination for 10 min at 5-min intervals. (i) In situ EPR signals of H2O2 over PCN and NV-PCN under illumination.

    XPS was used to detect the type and position of vacancies formed in the secondary roasting process. As shown in Table S1, NV-PCN (71.66%) had higher C/N (at.%) than PCN (71%), which proved that nitrogen vacancies (NV) were introduced in carbon nitride after secondary roasting. For PCN, the three characteristic peaks at 288.30, 285.90, and 284.72 eV in C1s XPS spectra (Figure S2) are attributable to N–C=N, C–NHx, and C=C (hybridized carbon in heptazine ring), respectively. The three characteristic peaks at 398.62, 399.30, and 400.85 eV in N1s XPS spectra of PCN (Figure 2d) are attributable to N–C=N, N3C, and NHX, respectively.16 The corresponding characteristic C1s and N1s N–C=N peaks of NV-PCN are shifted to lower binding energies compared with those of PCN, which can be attributed to the negative electron enrichment around NV. To verify the position of the N vacancy in NV-PCN, the relative content of different N species was analyzed, with results shown in Figure 2d. The peak-area ratio of N3C decreased from 35.62% in PCN to 28.84% in NV-PCN, which indicates that N3C defects were introduced in NV-PCN. As shown in Figure S3, N3C has two different positions: site ① and site ②. The out-of-plane heptazine bending modes in PCN and NV-PCN remain unchanged (Figure 2c), which excludes the generation of N3C defects at site ①. Based on these results, the structure of NV-PCN catalyst was deduced (Figure 2e).

    Since NV-PCN was used as a PDT agent for cancer therapy, its optical properties and band structure were examined by UV-vis diffuse reflectance spectra, Tauc plots, and Mott–Schottky plots. As shown in the inset in Figure 2f, the bandgap (Eg) of PCN is 2.78 eV, which caused by the n–π* electronic transitions of the conjugated PCN framework and is close to that reported for graphitic carbon nitride.17 Compared with PCN, NV-PCN shows larger Eg of 2.85 eV, which is attributable to the quantum confinement effect induced by the smaller nanosheet of NV-PCN than PCN.18 The slightly stronger light-absorption capacity for visible light of NV-PCN than PCN (Figure 2f) might attributable to the midgap state introduced by NV.19 In addition, a Mott–Schottky plot was used to obtain the semiconductor type and flat-band position of the PCN and NV-PCN samples. As illustrated in Figure S4, the slopes of the linear parts in the two curves are positive, indicating the typical n-type semiconductor characteristics of PCN and NV-PCN.20 The flat-band potentials (Efb) of PCN and NV-PCN were determined to be −1.07 and −1.16 eV (vs Ag/AgCl at pH 6.6), corresponding to the conduction-band potential at −0.48 and −0.57 eV (vs RHE) (relevant equations: E(NHE) = E(Ag/AgCl) + 0.197, E(RHE) = E(NHE) + 0.0591 × pH).21 Then, the valence-band position was calculated by adding the conduction-band potential to the bandgap, which was 2.30 eV (PCN) and 2.28 eV (NV-PCN). Based on these results, the band structures of PCN and NV-PCN were deduced, and these are shown in Figure 2g. Therefore, PCN and NV-PCN have suitable band structures to catalyze the reaction of H2O2/•OH+ OH.

    In situ DRIFT spectroscopy measurements (conducted in a confined space and purged for 10 min after adding H2O2) were performed to reveal the mechanism of photocatalytic •OH generation over PCN and NV-PCN. As shown in Figure 2h, compared with the pristine PCN, the peak intensity is significantly enhanced after introducing NV, indicating that NV facilitates the adsorption of H2O2 on carbon nitride. The peaks at 1602, 1405, and 854 cm−1 can correspond to the stretching vibrations of the N–C=N bond of NV-PCN, CN–O bond between NV-PCN and H2O2, and HO–OH bonds of H2O2, respectively.22 For NV-PCN, all peaks become weaker as light-irradiation time increases and the HO–OH stretching vibration peak moves to the direction of the high wave from 850 to 856 cm−1, which is attributable to the reduction in H2O2 by photoelectrons on NV-PCN into •OH and OH. Therefore, we speculate that H2O2 is adsorbed on the N site of the heptazine ring attached to NV on NV-PCN.

    To evaluate the ability of PCN and NV-PCN to generate •OH, we examined the in situ EPR spectrum to measure •OH. Figure 2i exhibits the characteristic 1:2:2:1 •OH radical signal at different time points,23 indicating that both PCN and NV-PCN catalysts can reduce H2O2 to •OH. For PCN, •OH increases within 1–3 min, but stabilizes at 4 min, which means that the production of •OH equals annihilation.24 For NV-PCN, •OH continues to rise within 1–4 min, and the overall signal intensity on NV-PCN is much more prominent than that on PCN, indicating the stronger ability of of NV-PCN to produce •OH than PCN with equivalent PCN (×1) and even higher than threefold PCN (×3) at 4 min (Figure S5), which is attributable to the more active sites for reduction of H2O2 on NV-PCN than that on PCN.

    NV-PCN Upregulated •OH Expression in Cal-27 Cells under LED Irradiation

    PDT is an innovative approach in cancer treatment, offering distinct advantages over conventional therapeutic methods, such as low toxicity, precision, spatiotemporal control, and minimal invasiveness.25 To circumvent the resistance to O2-dependent PDT in hypoxic tumors, we designed a novel non-O2-dependent type I photosensitizer—NV-PCN. It is well established that the level of H2O2 in cancer cells is significantly higher than that in normal cells.26 The aim of this research was to utilize NV-PCN to convert the overexpressed H2O2 within tumors into highly toxic •OH, thereby destroying cancer cells. Although the generation of •OH has been investigated in material characterization, further investigation is warranted to explore its potential in biological applications.

    Therefore, to further validate NV-PCN–promoted tumoral •OH expression by PDT, Cal-27 cells were cocultured with NV-PCN and intracellular •OH levels determined using an •OH probe, which can react with •OH generated from the reduction of H2O2 to emit green fluorescence. In Figure 3a, the intracellular •OH was detected via flow-cytometry analysis and CLSM imaging, respectively. As shown in Figure 3b, the ratio of •OH-producing cells is significantly increased in the NV-PCN + light group, indicating that more •OH was generated. In Figure 3c, we can clearly see that the NV-PCN + light group exhibits stronger green fluorescence intensity, indicating NV-PCN possesses similar photocatalytic activity in biological applications. In that case, we propose that NV-PCN, a novel light photocatalyst, can act as a Fenton-like agent to augment efficient intracellular expression of •OH and induce cell apoptosis, thus achieving PDT.

    Figure 3 PDT definitely promoted tumoral •OH expression in vitro. (a)Depicts a schematic diagram of detecting intracellular •OH in Cal-27 cells that have been pre-exposed to light, utilizing a •OH fluorescent probe. (b) Flow-cytometry analysis of •OH production in Cal-27 cells. (c) CLSM images of Cal-27 cells exposed to various conditions, where green fluorescence reflects •OH expression.

    In Vitro Anticancer Effects of NV-PCN Irradiated with LED Light

    Prior to assessing the therapeutic effects of NV-PCN upon white LED-light illumination, it was necessary to use the standard CCK-8 assay to evaluate the cytotoxic effects, which is a very important issue in the medical application of nanomaterials. After incubation with PCN and NV-PCN for 24 h, no obvious cytotoxicity was observed in Cal-27 cells, even at concentrations up to 1 mg·mL−1, indicating the negligible cytotoxicity of PCN and NV-PCN (Figure 4a and b). By contrast, when exposed to white LED light, cell viability gradually declined with increasing concentrations of NV-PCN, and the cell viability of the group incubated with 2 mg·mL−1 NV-PCN was the lowest among all groups. Nevertheless, even under nonirradiated conditions, 2 mg·mL−1 NV-PCN still affected cell viability. Therefore, we selected 1 mg·mL−1 as the optimal concentration for subsequent cell experiments. When adding isopropanol (scavenger of •OH)27 into the system (NV-PCN + light group), cell viability was significantly enhanced (Figure 5a), which showed that •OH played an key role in the NV-PCN photocatalytic inactivation of cancer cells. In addition, the larger red fluorescence area in the live and dead images for the NV-PCN + light group corroborates the results of the CCK-8 assay (Figure S6). The results suggest that NV-PCN not only possesses great biocompatibility but also exhibits more efficient photodynamic killing ability of cancer cells than PCN under illumination. Therefore, this study deeply investigated the biological properties of NV-PCN.

    Figure 4 (a) Optimal concentrations of NV-PCN acting on cells under light and dark conditions. **P<0.01, ****P<0.0001 compared to 0 μg/mL NV-PCN + light. (b) Hemolysis values of various samples collected from the supernatants. ****P<0.0001 compared to the other groups.

    Figure 5 NV-PCN as a photosensitizer induces dual damage to cancer nuclear DNA and mitochondria. (a) Relative viability of Cal-27 cells incubated with PCN and NV-PCN at a concentration of 1 mg·cm−1 for 24 h with white LED light illumination for 30 min. (b) Cellular uptake evaluation of Cal-27 cells treated with NV-PCN for 0.5–6 h using CLSM images. (c) Immunofluorescence images of γH2AX foci (green) in Cal-27 cells treated withcontrol, NV-PCN, light, Ce6 + light, and NV-PCN + light. Cell nuclei were stained with DAPI (blue). (d) Confocal microscopy images of the JC-1 probe in Cal-27 cells. (e) Flow cytometry of total ROS generation in Cal-27 cells under different treatments using DCFH-DA as intracellular total ROS indicator. Significance calculated by one-way ANOVA: *P<0.05, ****P<0.0001 compared to the control group.

    Next, assessment of the capacity of internalizing sufficient NV-PCN in cancer cells was conducted, because this is critical for further therapeutic effects. Dark-field scattering microscopy was used to visualize the intracellular distribution of NV-PCN. There was obvious signal enhancement in the NV-PCN group compared with the control group, showing the efficient uptake of NV-PCN by Cal-27 cells (Figure S7). As shown in Figure 5b, green fluorescence derived from NV-PCN is mainly concentrated in the cytoplasm and nucleus and intensifies with prolonged incubation time, indicating that the effective cellular uptake of NV-PCN is dependent on incubation duration.

    NV-PCN, a potent photosensitizer, converts intracellular H2O2 to •OH under white LED-light irradiation. Among ROS, •OH exerts greater damage to cancer cells due to its more aggressive effect on nuclei, inducing DNA double-strand breaks.28 Here, we evaluated DNA double-strand breaks by γH2AX staining using immunofluorescence labeling (green) and Western blot. The results showed that a prominently higher density of γH2AX foci occurred in the NV-PCN + light and Ce6 + light group than in the control, light, and NV-PCN-alone groups (Figure 5c and S8), indicating that NV-PCN and Ce6 can greatly increase light-induced DNA damage. However, it has been observed that the occurrence of DNA damage in cancer cells promotes the initiation of DNA damage–repair mechanisms, which results in tumor resistance.29

    Moreover, •OH has the potential to induce mitochondrial damage due to the superior reactivity of •OH.30 Considering this, the mitochondrial functions of the different groups were evaluated by analyzing the MMP of cells. As depicted in Figure 5d, when compared with the single-treatment groups (control, NV-PCN, and light), Cal-27 cells treated with Ce6 and NV-PCN irradiated with light transformed more JC-1 polymer to JC-1 monomer on the mitochondria, suggesting declining MMP in Cal-27 cells, especially in the NV-PCN + light group, revealing that more •OH produced by NV-PCN during PDT eventuates in mitochondrial dysfunction. Ce6, an FDA-approved type II photosensitizer, predominantly functions by leveraging the available oxygen in tumors to generate singlet oxygen, a key mechanism behind its therapeutic effectiveness. Nonetheless, the tumor microenvironment is inherently hypoxic, implying that it lacks the sufficient substrate necessary for the generation of reactive oxygen species (ROS) that are crucial for inflicting mitochondrial damage.31 Mitochondria regulate ROS and maintain cellular redox balance. Dysfunction in mitochondria boosts ROS, aggravating DNA damage and possibly leading to cellular dysfunction and disease progression.32 To further verify the total intracellular ROS generation of NV-PCN under LED illumination, DCFH-DA was used as a fluorescent probe to monitor the intracellular production of ROS. DCFH-DA is hydrolyzed by esterase after entering the cell to form DCFH, which can react with ROS in cells and exhibit green fluorescence. Notably, intense green fluorescence was observed in the NV-PCN + light (Figure S9). In contrast, negligible fluorescence was observed in the control, NV-PCN, and light groups. We also quantitatively detected the generation levels of total intracellular ROS in Cal-27 cells using flow cytometry (Figure 5e), and obtained similar results to the aforementioned.

    In eukaryotic cells, mitochondria are critical for regulating intracellular energy.33 After mitochondrial damage, intracellular ATP content decreases.34 As shown in Figure 6a, compared with the single-treatment groups, the ATP content of the NV-PCN + light group was significantly reduced, leading to the downregulation of DNA-damage repair. However, the Ce6 + light group exhibited enhanced damage repair compared to the NV-PCN + light group. 53BP1 and GADD45A, key factors in the DNA damage–repair process,35,36 were further evaluated. NV-PCN + light treatment markedly decreased the protein expression of 53BP1 and GADD45A (Figure 6b). Additionally, the downregulation of 53BP1 and GADD45A was further confirmed by Western blot analysis (Figure 6c), and cancer cells treated with NV-PCN + light exhibited failed DNA-damage repair.

    Figure 6 NV-PCN-mediated PDT promoted Cal-27 cell apoptosis. (a) Intracellular ATP levels of Cal-27 cells after various treatments. (b) Expression of 53BP1 and GADD45A in Cal-27 cells examined by fluorescence microscopy. (c) Expression levels of γH2AX, GADD45A, 53BP1, pro-caspase 3, cleaved caspase 3, and β-actin proteins in cells treated for 24 h in different groups detected by Western blot experiments. β-actin protein was used as the internal control. (d) EDU assay of Cal-27 cells with control, NV-PCN, light, Ce6 + light, and NV-PCN + light. (e) Transwell assay of Cal-27 cells with control, NV-PCN, light, Ce6 + light, and NV-PCN + light. The concentration of NV-PCN was 1 mg·mL−1. Significance calculated by one-way ANOVA: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

    Then, we evaluated their therapeutic effects upon light irradiation by EDU assays. As illustrated in Figure S10, there was 80%, 76%, and 60% cell proliferation of Cal-27 cells after treatment by NV-PCN alone, light alone, and Ce6 + light, respectively, while only 26% survived under NV-PCN + light treatment (smaller red fluorescence area, Figure 6d). Similarly, the Transwell assays revealed less cell migration in the NV-PCN + light group than in the other three groups (Figure 6e). These results, along with previous findings, raise the possibility that compared to Ce6, NV-PCN would induce a more powerful anticancer effect due to enhancing ROS generation and inhibiting cancer-cell proliferation under light irradiation.37

    In addition, flow cytometry was utilized to quantitatively detect cell apoptosis under various treatments by annexin V–FITC/propidium iodide double staining. As shown in Figure 7a, no obvious apoptosis (early apoptosis or late apoptosis) was detected in the control, NV-PCN-, or light-alone groups. On the contrary, when the cells were treated with Ce6 and NV-PCN under light irradiation, early-apoptosis cells and late-apoptosis cells increased to 3.55% and 3.66% and to 14.51% and 33.42%, respectively. The results of Western blot and immunofluorescence analysis further confirmed that the apoptosis-related protein cleaved caspase 3 was activated and its expression was significantly greater in the NV-PCN+ light group than in the other groups (Figure 6c, 7b), indicating that NV-PCN + light cotreatment induces a powerful PDT effect and effectively triggers tumor-cell apoptosis. Taken together, these results indicate that the as-prepared NV-PCN under LED irradiation enhanced anticancer activity by inducing •OH-mediated DNA damage and mitochondrial dysfunction, downregulating ATP, amplifying ROS storms, inhibiting DNA-damage repair, and upregulating apoptosis-related proteins.

    Figure 7 (a) Qualitative flow-cytometry data plot indicating the increase in apoptosis of Cal-27 cells after different treatments for 24 h. (b) Immunofluorescence images of cleaved caspase 3 (green) in Cal-27 cells treated with control, NV-PCN, light, Ce6 + light, and NV-PCN + light. Cell nuclei were stained with DAPI (blue).

    In Vivo Antitumor Therapeutic Effect and Biosafety of NV-PCN Irradiated with LED Light

    The excellent performance of NV-PCN at the cellular level prompted us to evaluate the PDT efficacy of NV-PCN on solid cancers in BALB/c nude mice bearing Cal-27 tumors. Animal experiments were performed according to the protocols approved by the Ethics Committee of the Second Hospital of Shanxi Medical University (DW2023049). The treatment protocol is shown in Figure 8a. Prior to conducting the antitumor study, the biodistribution of Cy5.5–NV-PCN after intratumoral injection was detected by tracking Cy5.5 fluorescence using an in vivo imaging system.38 As shown in Figure 8b, the long-term distribution of Cy5.5–NV-PCN fluorescence over 72 h indicates the excellent tumor-accumulation capacity of NV-PCN.39 It was observed that in addition to tumor tissue, kidney, one of the main metabolic organs, also exhibited much fluorescence aggregation compared with the control group within 6 h, indicating that some NV-PCN can be excreted mainly through the kidneys without apparent impacts on the remaining organs.

    Figure 8 In vivo antitumor effect of NV-PCN-mediated PDT. (a) Schematic of the therapeutic process for cancer-bearing nude mice. (b) Fluorescence images of Cal-27 cancer-bearing mice and ex vitro fluorescence images of major organs and tumor tissue after intratumoral injection of Cy5.5–NV-PCN at different time points. (c) Time-dependent surveillance of body weight for mice with different treatments over 22 days (n=4). (d) Time-dependent surveillance of tumor volume for mice with different treatments over 22 days (n=4). (e) Cancer images of each group derived from BALB/c mice at day 22 posttreatment. (f) H&E and immunohistochemical staining of tumor tissue of mice after various treatments. Significance calculated by one-way ANOVA: ****P<0.0001.

    Thereafter, the in vivo anticancer effects of NV-PCN–mediated PDT were investigated. During the experiments, the weight of mice in all groups changed slightly within 22 days (Figure 8c), suggesting that NV-PCN has no obvious systemic side effects in vivo. Compared with the control group and the single-treatment groups (NV-PCN, light), Ce6 + light and NV-PCN + light effectively suppressed tumor growth, with the NV-PCN + light group showing a more pronounced effect (Figure 8d). The satisfactory photosensitizing effect is attributed to the enhanced generation of ROS, leading to the death of cancer cells in an apoptosis pathway. After 22 days, all mice were euthanized to harvest tumor tissue (Figure 8e) and weigh them to directly explore the efficacy of different treatments. The tumor weights are shown in Figure 8e. Mice that received Ce6 + light and NV-PCN + light treatment had significantly smaller tumor volume, which matches well with the tumor-growth curves in Figure 8d, further indicating that NV-PCN presents significant advantages in anticancer therapy.40 The therapeutic effect was also confirmed by pathological results (Figure 8f). All groups showed varying degrees of tumor necrosis on H&E staining. Remarkably, the NV-PCN + light group showed tumor-tissue damage (approximately 75% and 80%). Moreover, cancer cells in the NV-PCN + light group exhibited the weakest Ki67 signal and the strongest TUNEL signal, showing that this treatment can maximally inhibit cell proliferation and promote cell apoptosis. It is particularly noteworthy that NV-PCN PDT was confirmed to effectively increase the expression of γH2AX and cleaved caspase 3, implying serious DNA damage and apoptosis.

    Nanomedicine safety is a critical concern in its application in biomedicine. Consequently, experiments including H&E staining of main organs and blood hematology were performed to ensure the safe application of NV-PCN and Ce6 in vivo. We collected the major organs (heart, liver, spleen, lung, and kidney) after different treatments for H&E staining, and the histological morphology of the major organs appeared unaffected in all the groups (Figure 9a). The blood biochemistry and hematology tests also showed negligible effects in the significant parameters (Figure 9b and c). All of these results demonstrate that NV-PCN, similar to Ce6, is a safe nanoplatform for cancer therapy.

    Figure 9 In vivo toxicity and safety assessment of NV-PCN. (a) Hematoxylin and eosin–stained tissue sections from the mice to monitor histological changes in heart, liver, spleen, lung, and kidney 22 days after intratumoral injection of the NV-PCN solution. (b) Blood biochemistry analysis of the mice treated with Ce6 and NV-PCN. (c) Blood hematology analyses of mice on the last day.

    Methods

    Catalyst Preparation

    Pristine PCN was obtained by annealing melamine powder (10 g) at 550°C for 240 min (heating rate 3°C min−1) and grinding it homogeneously under an air atmosphere. Subsequently, PCN (0.3 g) was subjected to annealing at 520°C for 60 min (heating rate of 10°C min−1) under an argon atmosphere to synthesize NV-PCN.

    Characterization

    Transmission electron microscopy (TEM) images were obtained using a Tecnai G2 F20 STwin. Before measurement, a dispersion solution of PCN and NV-PCN NSs was deposited on a carbon film supported by copper grids. X-ray diffraction (XRD) patterns were attained with a Bruker D8 Advance equipped with Cu Ka radiation (40 kV). Fourier-transform infrared (FTIR) spectra were recorded by a Bruker Tensor II spectrometer using a KBr pellet. X-ray photoelectron spectroscopy (XPS) was performed with a VG Scientific Escalab Mark II spectrometer. UV-vis diffuse reflectance spectra were obtained with a Shimadzu UV-3600 spectrometer. Electrochemical measurement was performed on a CHI 760E workstation using a conventional three-electrode configuration, where Ag/AgCl and platinum plates were used as reference and counter electrode, respectively. The working electrode was prepared by mixing catalyst (2.5 mg), water (300 μL), ethanol (200 μL), and Nafion (5 wt%, 25 μL) evenly. The slurry (20 μL) was then spread to 0.5 cm2 on a fluorine-doped tin oxide glass electrode. After the electrode had dried, the edge portion of the electrode was sealed with epoxy adhesive. Motto–Schottky plots and photocurrent signals were collected using 0.1 M of Na2SO4 solution as electrolyte. In situ DRIFT spectra were recorded in a sealed in-site reaction cell (equipped with Praying Mantis diffuse reflectance accessory and MCT detecor).

    The catalyst was added to the reaction cell and processed at 100°C under argon for 1 h. Then, 10 μL of H2O2 solution was added, purged for 10 min under argon conditions, and the test data obtained after the catalyst had started to illuminate. In situ electron paramagnetic resonance (EPR) measurements were conducted on a Bruker EMXplus 10/12 spectrometer. For preparation of the test samples, 5 mg of catalyst was ultrasonically dispersed in 1 mL of acetonitrile, and 45 μL of the above mixture and 5 µL of H2O2 were mixed with 20 μL of DMPO acetonitrile solution (1 mg·μL−1). The EPR spectra were measured at an interval of 30 seconds and swept for 30 seconds with no superposition of signals. A BD FACSCanto II flow cytometer was used to perform flow-cytometry analyses. A multifunctional microplate reader was used to perform cell-viability and hemolysis experiments (Infinite M1000 Pro, Tecan). A white light–emitting diode (LED) with emission centered at 400–600 nm purchased from Shenzhen Zhongyu Technology (China) was used as the white-light source. The intensity of the white LED for photocatalysis and PDT was 50 mW·cm−2 for 30 min.

    Cell Culture

    Human oral squamous carcinoma cells (Cal-27) were obtained from the Chinese Academy of Sciences Cell Bank (Shanghai, China). Cal-27 cells were kept in DMEM (Gibco) supplemented with 10% FBS, 1% penicillin–streptomycin and 1% L-glutamine (Meilunbio) at 37°C in a cell incubator (Thermo Scientific) containing 5% CO2. For cell passage, cells were digested with 0.25% trypsin–EDTA (Gibco) and then resuspended in fresh culture medium.

    Measurement of Endogenous •OH

    After coculturing NV-PCN or Ce6 and Cal-27 cells in a 24-well plate (1×105 cells/well) for 6 h, cells were exposed or received no exposure to LED irradiation (50 mW·cm−2, 30 min). The culture medium was removed and each well washed repeatedly with PBS. Subsequently, the cells were incubated with HKOH-1r (MCE, HY-D1159) in a cell incubator for 30 min. •OH level was detected and quantified using confocal laser scanning microscopy (CLSM, Olympus, FV3000) and flow cytometry (Agilent Corporation, NovoCyte).

    Cellular Uptake

    The Cal-27 cells were seeded in 24-well plates (1×105 cells/well) and cultured for 24 h. After incubation with NV-PCN, Cal-27 cells were fixed with 4% paraformaldehyde (PFA, Leagene), stained with DAPI (Beyotime), and finally the uptake of Cal-27 cells was observed with CLSM.

    Cytotoxicity Assay

    Cell viability was assessed using Cell Counting Kit 8 (CCK-8). The Cal-27 cells were cultured in 96-well plates (1.2×104 cells/well). After 24 h of incubation, the cells were treated with NV-PCN (1 mg·mL−1, 100 µL) for 6 h and then irradiated with the white LED (50 mW·cm−2, 30 min). After 24 h, 100 μL of fresh DMEM containing CCK-8 (10%) was added and the treatment continued at 37°C for 30 min. Absorbance was then measured at 450 nm using a full-wavelength enzymograph (SpecteaMax plus 384, USA) to assess cell viability.

    A fluorescent live/dead cell assay was applied to visualize the cell viability of NV-PCN combined with visible light irradiation in Cal-27 cells. Typically, the cells were treated using the same method as described above and then stained with a Live/Dead Cell Staining Kit (BestBio, China) in accordance with the manufacturer’s instruction. Afterwards, live and dead cells, emitting green and red fluorescence, respectively, were observed using CLSM.

    In addition, hemocompatibility assays were used to measure the cytotoxicity of NV-PCN. Fresh blood was obtained from BALB/c mice, red blood cells acquired via centrifugation (3000 rpm, 15 min), and then these were mixed with NV-PCN concentrations of 200, 400, 600, 800, and 1000 ug·mL−1. PBS and ddH2O were set as the negative and positive control group, respectively. After incubation for 4 h, the solution was centrifuged (3000 rpm, 15 min) and the absorbance spectra of the supernatant were measured at 540 nm.

    DNA Damage by NV-PCN

    Cal-27 cells (1×105/well) were seeded into 24-well plates for 24 h and then incubated with NV-PCN or Ce6 (1 mg·mL−1, 500 µL) for 6 h. Next, those cells were exposed or received no exposure to LED irradiation. PFA (4%) and Triton X-100 (0.5%) were used to fix and permeate the cells, respectively. Then, the cells were treated with blocking buffer (1% BSA, 30 min) at room temperature and further incubated with anti-phospho-histone γH2AX rabbit monoclonal antibody (UpingBio, YP-Ab-01510, dilution 1:1000) at 4°C overnight. Then, fluorescein isothiocyanate (FITC; Beyotime Biotechnology, dilution 1:800) was added and incubated at room temperature for 1 h after being washed with PBS three times to remove excess antibody. Cell nuclei were stained by DAPI for 5 min. Finally, fluorescence images were acquired with CLSM.

    Mitochondrial Membrane Potential Analysis

    Cal-27 cells were inoculated in 24-well plates (1×105 cells/well) for 24 h. The cells were then treated with control, NV-PCN, and Ce6 in the dark for 6 h with or without LED irradiation. JC-1 dyeing solution (configured according to manufacturer’s instructions) was then added and incubated at 37°C for 20 min. Finally, the cells were washed three times with JC-1 dye buffer and images taken by CLSM.

    Total Intracellular ROS Generation

    Cal-27 cells (2 × 106/well) were seeded into six-well plates. Five groups were set: (a) control, (b) NV-PCN, (c) light only, (d) Ce6 + light, and (e) NV-PCN + light. Then, cells in the corresponding groups were incubated with control, NV-PCN, and Ce6 (1 mg·mL−1, 500 µL). After 6 h, the 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA; Meilunbio, MA0219) was added as a fluorescence probe and the mixture incubated in the dark for 30 min. Afterwards, groups (c), (d), and (e) were disposed of” modified to “Afterwards, groups (c), (d), and (e) were exposed to illumination. Finally, flow cytometry and fluorescence microscopy (Leica, Germany) were used to study the generation of intracellular ROS.

    Detection of Intracellular ATP

    The Cal-27 cells were cultured in 96-well plates (1.2×104 cells/well). After 24 h of incubation, the cells were treated with NV-PCN and Ce6 (1 mg·mL−1, 100 µL) for 6 h, followed by light irradiation, then after incubation for another 24 h, the cells were collected. In conjunction with an ATP chemiluminescence assay kit (Elabscience, E-BC-F002), the fluorescence value of each well was detected by a Varioskan multifunctional enzyme labeler (Thermo Scientific, Varioskan LuX).

    Immunofluorescence Staining

    The Cal-27 cells were seeded into 24-well plates (1×105 cells/well) for 24 h and then incubated with NV-PCN and Ce6 (1 mg·mL−1, 500 µL) for 6 h. Next, they were exposed or received no exposure to LED irradiation. PFA (%) and Triton X-100 (0.5% were used to fix and permeate the cells, respectively. Then, the cells were treated with blocking buffer (1% BSA, 30 min) at room temperature and further incubated with 53BP1 (Beyotime), GADD45A (Bioss), and cleaved caspase 3 (Uping Bio) primary antibody at 4°C overnight. Subsequently, Cy5-labeled or FITC-labeled (Beyotime Biotechnology, dilution 1:800) goat anti-rabbit IgG was added and incubated at room temperature for 1 h after being washed with PBS three times to remove excess antibody. Cell nuclei were stained with DAPI for 5 min. Finally, fluorescence images were acquired with CLSM.

    In Vitro Anticancer Effect of NV-PCN

    The Cal-27 cells were seeded in 24-well plates (1×105 cells/well) for 24 h and treated with NV-PCN or Ce6 for 6 h. To evaluate the PDT effect, the cells were exposed or received no exposure to LED irradiation. The cells were then analyzed using 5-ethinyl-2’-deoxyuridine (EdU; KeyGen), Transwell assays, and annexin V–FITC/propidium iodide (KeyGen, Nanjing, China) in accordance with the manufacturer’s guidelines.

    Western Blotting Assay

    The Cal-27 cells were seeded in a six-well plate (2 × 106 cells/well) and cultured for 24 h. Then, NV-PCN (1 mg⋅mL−1) was added to two groups (NV-PCN and NV-PCN + light) for 6 h. The cells of the light or NV-PCN + light group were irradiated with white LED light (50 mW·cm−2, 30 min). After 24 h of incubation, cells were collected and lysed by precooled RIPA buffer for 30 min. After centrifugation (12,000 rpm) for 20 min at 4°C, the supernatant was mixed with the loading buffer and protein concentrations of the four groups determined using a BCA protein assay kit (KeyGen, BioTECH). Proteins were then separated and transferred. The membranes were blocked at room temperature (protein-free rapid blocking solution, Boster) for 20 min. After that, the membranes were incubated with primary antibodies overnight at 4°C. These antibodies were pro-caspase 3 (UpingBio, YP-Ab-00345, dilution 1:1500), cleaved caspase 3 (UpingBio, YP-Ab-00003, dilution 1:1500), γH2AX (UpingBio, dilution 1:1000), GADD45A (Bioss, bs-1360R, dilution: 1:200), 53BP1 (Abcam, ab243868, dion:luti 1:1000), and β-actin (ABclonal, AC038, dilution 1:10,000). Then, the membranes were washed and incubated with HRP-conjugated secondary antibody (UpingBio, YP848537-H, dilution 1:10000) for 1 h. Finally, stained with the ECL detection kit (Meilunbio, MA0186), the protein bands were observed using Compass software (Bio-Rad chemidoc XRS+, Universal Hood II) and the appropriate protein gray values calculated.

    Transwell Assay

    The migration ability of Cal-27 cells was detected by a Transwell assay. Cal-27 cells were seeded in 6-well plates at a density of 2×106 cells per well. After 24 h, the cells were treated with NV-PCN (1 mg·mL−1, 100 µL) for 6 h and then irradiated with white LED light (50 mW·cm−2, 30 min) for another 24 h. The upper chambers of Transwell plates (Corning Inc.; Corning, NY, USA) use 8.0 μm-pore filters. Cal-27 cells in different groups were collected and seeded on the upper chambers (1.0 × 105 cells per chamber) in 200 μL serum-free medium. In contrast, the lower chambers were filled with 600 μL of DMEM medium containing 20% (V/V) FBS to induce cell invasion. After 24 h, the non-invading cells on the upper side of the filters were removed, and the invading cells on the lower side were fixed with 4% (W/V) PBS-buffered PFA for 30 min and stained with 0.2% (W/V) crystal violet for 10 min. The stained cells were visualized and counted in three random fields using an inverted microscope.

    In Vivo Biodistribution and Cancer Accumulation of NV-PCN

    In order to evaluate the in vivo biodistribution of NV-PCN, the healthy mice were intratumorally injected with Cy5.5-labeled NV-PCN (5 mg·mL−1, 50 μL). At time points of 1 min, 30 min, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 72 h), the mice were euthanized to collect the main organs (heart, liver, spleen, lung, and kidney) and tumor tissue. Fluorescence was visualized with a small-animal live optical 3D imaging system (PerkinElmer, IVIS Spectrum). Based on in vivo imaging-system observations, mice were euthanized after injection of Cy5.5–NV-PCN at different time points, and then the harvested cancer tissue and major organs were analyzed by ex vivo fluorescence imaging.

    In Vivo Anticancer Effects of NV-PCN

    To construct a tumor-bearing BALB/c mouse model, harvested Cal-27 cells were suspended in a suitable amount of PBS. Cancer cells were injected into the proximal axilla of the right hind limbs of mice to construct an OSCC mouse model. The mice were then injected with 50 µL (2 × 107 cells) of the suspension into their right hind-limb axilla. When tumors had grown to 100 mm3, the mice were divided into four groups——–—(a) PBS, (b) NV-PCN, (c) light only, (d) Ce6 + light, and (e) NV-PCN + light—that were treated with PBS, NV-PCN, or Ce6 solution via intratumoral injection every 2 days for a total of four times with or without light irradiation. The tumor volume was measured with a vernier caliper and calculated as (length × width2)/2 for 22 days. After euthanasia, the cancer tissue and main organs (heart, liver, spleen, lung, kidney) were weighed, fixed in 4% PFA solution, and tissue slices embedded in paraffin. For further evidence of cancer apoptosis, tumor slices were stained with HE, Ki67 (Abcam, ab15580), Tunel (Beyotime), γH2AX, and cleaved caspase 3 antibody, and immunofluorescence images were captured by CLSM.

    In Vivo Safety Assessment

    Blood samples were collected from each group. About 100 μL of the samples were treated with anticoagulant (potassium EDTA) for hematology analysis. The residual blood was precipitated at room temperature for 2 h, and the plasma was collected by centrifugation at 3500 g for 10 min to assess liver (AST, ALT) and kidney (CRE, urea) function indices. Additionally, main organs (heart, liver, spleen, lung, kidney) were stained with H&E to observe changes in tissue structure using light microscopy. All analyses were conducted at Wuhan Xavier Biotechnology.

    Statistical Analysis

    All data are presented as means ± standard deviation (SD) of at least three independent replicates for each experiment. Statistical analysis was performed using GraphPad Prism 9. Data were compared using Student’s t test and one-way ANOVA. Statistical differences are indicated by asterisks in the figures: *P<0.05, **P<0.01, and ***P<0.001.

    Conclusion

    In summary, we designed nitrogen vacancy (NV)–modified PCN (NV-PCN) for PDT of Cal-27 cell-induced OSCC that effectively induced Cal-27-cell apoptosis by triggering DNA damage and inhibiting DNA-damage repair. The introduction of NV not only further improved the cell accessibility of PCN by increasing the content of –NH2 but also provided reactive sites for H2O2 reduction and facilitated carrier separation, which are beneficial for large-scale production of •OH. Moreover, EPR and intracellular •OH assays revealed that NV-PCN exhibited superior •OH-generation efficiency under visible-light irradiation. Therefore, NV-PCN leads to the explosion of •OH around the nuclei and mitochondria of Cal-27 cells under illumination, which effectively kills Cal-27 cells via synchronously leading to nucleus DNA damage and mitochondrial dysfunction. Then, mitochondrial dysfunction triggers an ROS storm to intensify DNA damage. It also attenuates the ATP energy chain to inhibit DNA-damage repair. Compared to the O2-dependent photosensitizer Ce6, NV-PCN-based PDT has stronger antitumor efficacy in vitro and in vivo. Therefore, this kind of nanoparticle not only represents an efficient photosensitizer for enhanced PDT of cancer but also opens up new avenues for in-depth study on carbon nitride-based cancer PDT.

    Ethics Approval and Consent to Participate

    The animal experiments were conducted in accordance with the Regulations on the Management of Laboratory Animals of Shanxi Province and Guidelines for the Care and Use of Laboratory Animals following the approval of the Ethics Committee of the Second Hospital of Shanxi Medical University (DW2023049). Every effort was made to reduce the number of mice used and alleviate their suffering.

    Acknowledgments

    Thank you to all the researchers in our laboratory for providing theoretical and technical support during the research.

    Author Contributions

    All authors made a significant contribution to the work reported, whether in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas, took part in drafting, revising, or critically reviewing the article, gave final approval to the version to be published, have agreed on the journal to which the article has been submitted, and agree to be accountable for all aspects of the work.

    Funding

    This work was supported by the National Natural Science Foundation of China (82071155, 82271023, and 82301052), Basic Research Project of Shanxi Province (202203021223006 and 202403021212211), Graduate Education Innovation Project of Shanxi Province (2023SJ139), Basic Research Project of Shanxi Province (202303021212131 and 202303021212132), and Health Commission of Shanxi Province (2022XM14).

    Disclosure

    The authors declare no competing interests.

    References

    1. Qian M, Cheng Z, Luo G, et al. Molybdenum diphosphide nanorods with laser-potentiated peroxidase catalytic/mild-photothermal therapy of oral cancer. Adv Sci Weinh Baden-Wurtt Ger. 2022;9(1):2101527. doi:10.1002/advs.202101527

    2. Yu L, Xu Z, Zhu G, et al. High-performance photodynamic therapy of tongue squamous cell carcinoma with multifunctional nano-verteporfin. Int J Nanomed. 2024;19:2611–2623. doi:10.2147/IJN.S452060

    3. Awwad SW, Serrano-Benitez A, Thomas JC, Gupta V, Jackson SP. Revolutionizing DNA repair research and cancer therapy with CRISPR-cas screens. Nat Rev Mol Cell Biol. 2023;24(7):477–494. doi:10.1038/s41580-022-00571-x

    4. Shi H, Carter OWL, Ponte F, et al. A photodynamic and photochemotherapeutic platinum‐iridium charge‐transfer conjugate for anticancer therapy. Angew Chem Int Ed. 2024;63(23):e202400476. doi:10.1002/anie.202400476

    5. Chen Q, Han L, Wu J, et al. A precise and intelligent nanomedicine for salivary adenoid cystic carcinoma treatment by combining antivascular photodynamic therapy and neuroinhibitory chemotherapy. Adv Funct Mater. 2024;34(13):2312732. doi:10.1002/adfm.202312732

    6. Lietke S, Schmutzer M, Schwartz C, et al. Interstitial photodynamic therapy using 5-ALA for malignant glioma recurrences. Cancers. 2021;13(8):1767. doi:10.3390/cancers13081767

    7. Xu S, Zhu X, Zhang C, Huang W, Zhou Y, Yan D. Oxygen and Pt(II) self-generating conjugate for synergistic photo-chemo therapy of hypoxic tumor. Nat Commun. 2018;9(1):2053. doi:10.1038/s41467-018-04318-1

    8. Qing L, Shenshen W, Bin L, et al. “All‐in‐One” MnO2@PtAuRu nanoreactor for self‐replenishing and cascade catalytic therapy of cancer. Small. 2024. doi:10.1002/smll.202405321

    9. Du J, Zhou M, Chen Q, et al. Disrupting intracellular iron homeostasis by engineered metal-organic framework for nanocatalytic tumor therapy in synergy with autophagy amplification-promoted ferroptosis. Adv Funct Mater. 2023;34(17). doi:10.1002/adfm.202215244

    10. Li D, Liu P, Tan Y, et al. Type I photosensitizers based on aggregation-induced emission: a rising star in photodynamic therapy. Biosensors. 2022;12(9):9. doi:10.3390/bios12090722

    11. Bundy K, Kelly R, Brown E, Delahunty C. pH shifts and precipitation associated with metal ions in tissue culture. Biomaterials. 1985;6(2):89–96. doi:10.1016/0142-9612(85)90069-9

    12. Zheng Y, Zhang L, Li Y, et al. Triptycene incorporated carbon nitride based donor-acceptor conjugated polymers with superior visible-light photocatalytic activities. J Colloid Interface Sci. 2022;622:675–689. doi:10.1016/j.jcis.2022.04.138

    13. Xia P, Cao S, Zhu B, et al. Designing a 0D/2D S-scheme heterojunction over polymeric carbon nitride for visible-light photocatalytic inactivation of bacteria. Angew Chem Int Ed Engl. 2020;59(13):5218–5225. doi:10.1002/anie.201916012

    14. Wang Y, Godin R, Durrant JR, Tang J. Efficient hole trapping in carbon dot/oxygen-modified carbon nitride heterojunction photocatalysts for enhanced methanol production from CO(2) under neutral conditions. Angew Chem Int Ed Engl. 2021;60(38):20811–20816. doi:10.1002/anie.202105570

    15. Zhao D, Dong C-L, Wang B, et al. Synergy of dopants and defects in graphitic carbon nitride with exceptionally modulated band structures for efficient photocatalytic oxygen evolution. Adv Mater Deerfield Beach Fla. 2019;31(43):e1903545. doi:10.1002/adma.201903545

    16. Palmer M, Björklund H, Olson L, Hoffer B. Trophic effects of brain areas on the developing cerebral cortex: II. electrophysiology of intraocular grafts. Brain Res. 1983;282(2):141–148. doi:10.1016/0165-3806(83)90092-5

    17. Wu C, Yu G, Yin Y, et al. Mesoporous polymeric cyanamide-triazole-heptazine photocatalysts for highly-efficient water splitting. Small Weinh Bergstr Ger. 2020;16(37):e2003162. doi:10.1002/smll.202003162

    18. Zhang Y, Huang Z, Dong C, et al. Synergistic effect of nitrogen vacancy on ultrathin graphitic carbon nitride porous nanosheets for highly efficient photocatalytic H2 evolution. Chem Eng J. 2022;431:134101. doi:10.1016/j.cej.2021.134101

    19. Antil B, Kumar L, Reddy K, Gopinath C, Deka S. Direct thermal polymerization approach to N-rich holey carbon nitride nanosheets and their promising photocatalytic H2 evolution and charge-storage activities. ACS Sustain Chem Eng. 2019;7(10):9428–9438. doi:10.1021/acssuschemeng.9b00626

    20. Zhang G, Xu Y, Rauf M, et al. Breaking the limitation of elevated coulomb interaction in crystalline carbon nitride for visible and near-infrared light photoactivity. Adv Sci Weinh Baden-Wurtt Ger. 2022;9(21):e2201677. doi:10.1002/advs.202201677

    21. Tang H, Xia Z, Chen R, Liu Q, Zhou T. Oxygen doped G-C(3) N(4) with nitrogen vacancy for enhanced photocatalytic hydrogen evolution. Chem Asian J. 2020;15(21):3456–3461. doi:10.1002/asia.202000912

    22. Liu M, Liu J, Zeng Z, et al. Steric hindrance effect induced photopurification of styrene oxide over surface modified polymeric carbon nitride. Sep Purif Technol. 2022;300:121929. doi:10.1016/j.seppur.2022.121929

    23. Zhang X, He C, Chen Y, et al. Cyclic reactions-mediated self-supply of H(2)O(2) and O(2) for cooperative chemodynamic/starvation cancer therapy. Biomaterials. 2021;275:120987. doi:10.1016/j.biomaterials.2021.120987

    24. He Z, Guo Y, Chen J, et al. Unsaturated phospholipid modified FeOCl nanosheets for enhancing tumor ferroptosis. J Mater Chem B. 2023;11(9):1891–1903. doi:10.1039/d2tb01854c

    25. Huang R, Ni N, Su Y, et al. Chargeable persistent luminescence 3d-printed scaffolds: a stepwise tactic for osteosarcoma treatment. Chem Eng J. 2024;479:147436. doi:10.1016/j.cej.2023.147436

    26. Gao Y, Tong H, Li J, et al. Mitochondria-targeted nanomedicine for enhanced efficacy of cancer therapy. Front Bioeng Biotechnol. 2021;9:720508. doi:10.3389/fbioe.2021.720508

    27. Xu W, Kang Y, Jiao L, et al. Tuning atomically dispersed fe sites in metal-organic frameworks boosts peroxidase-like activity for sensitive biosensing. Nano-Micro Lett. 2020;12(1):184. doi:10.1007/s40820-020-00520-3

    28. Xu M, Qian Y, Li X, et al. Janus ACSP nanoparticle for synergistic chemodynamic therapy and radiosensitization. ACS Appl Mater Interfaces. 2024;16(14):17242–17252. doi:10.1021/acsami.4c00499

    29. Wang Y, Gao B, Zhang L, et al. Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nat Commun. 2024;15(1):1568. doi:10.1038/s41467-024-45693-2

    30. Ding X, Wang T, Bai S, et al. A dual heat shock protein down-regulation strategy using PDA/Cu/ICG/R controlled by nir “switch” enhances mild-photothermal therapy effect. Adv Healthc Mater. 2023;12(27):e2300929. doi:10.1002/adhm.202300929

    31. Zhang Y, Jia R, Wang X, et al. Targeted delivery of catalase and photosensitizer Ce6 by a tumor-specific aptamer is effective against bladder cancer in vivo. Mol Pharm. 2024;21(4):1705–1718. doi:10.1021/acs.molpharmaceut.3c01047

    32. Miyakawa Y, Otsuka M, Shibata C, et al. Gut bacteria-derived membrane vesicles induce colonic dysplasia by inducing DNA damage in colon epithelial cells. Cell Mol Gastroenterol Hepatol. 2024;17(5):745–767. doi:10.1016/j.jcmgh.2024.01.010

    33. Feng X, Lin T, Chen D, et al. Mitochondria-associated ER stress evokes immunogenic cell death through the ROS-PERK-eIF2α pathway under PTT/CDT combined therapy. Acta Biomater. 2023;160:211–224. doi:10.1016/j.actbio.2023.02.011

    34. Duan C, Wang Z, Wu J, et al. Fut2 deficiency promotes intestinal stem cell aging by damaging mitochondrial functions via down-regulating Α1,2-fucosylation of Asah2 and Npc1. Res Wash DC. 2024;7:0343. doi:10.34133/research.0343

    35. Zhao B, Ma Z, Ding S, et al. Catalytic MnWO4 nanorods for chemodynamic therapy synergized radiotherapy of triple negative breast cancer. Adv Funct Mater. 2023;33(47). doi:10.1002/adfm.202306328

    36. You W, Liu S, Ji J, et al. Growth arrest and DNA damage-inducible alpha regulates muscle repair and fat infiltration through atp synthase F1 subunit alpha. J Cachexia, Sarcopenia Muscle. 2023;14(1):326–341. doi:10.1002/jcsm.13134

    37. Guney Eskiler G, Deveci Ozkan A, Sozen Kucukkara E, Kamanlı AF, Gunoğlu B, Yıldız MZ. Optimization of 5-aminolevulinic acid-based photodynamic therapy protocol for breast cancer cells. Photodiagnosis Photodyn Ther. 2020;31:101854. doi:10.1016/j.pdpdt.2020.101854

    38. Guo H, Liu L, Hu Q, Dou H. Monodisperse ZIF-8@dextran nanoparticles co-loaded with hydrophilic and hydrophobic functional cargos for combined near-infrared fluorescence imaging and photothermal therapy. Acta Biomater. 2022;137:290–304. doi:10.1016/j.actbio.2021.10.006

    39. Chang R, Wang P-Y, Tseng C-L. New combination/application of polymer-based nanoparticles for biomedical engineering. Adv Exp Med Biol. 2018;1078:271–290. doi:10.1007/978-981-13-0950-2_14

    40. Bhanja D, Wilding H, Baroz A, et al. Photodynamic therapy for glioblastoma: illuminating the path toward clinical applicability. Cancers. 2023;15(13):13. doi:10.3390/cancers15133427

    Continue Reading

  • Trump says Iran has not agreed to inspections, give up enrichment – Reuters

    1. Trump says Iran has not agreed to inspections, give up enrichment  Reuters
    2. Iran has not agreed to inspections or given up enrichment, says Trump  Al Jazeera
    3. Donald Trump’s claim about Iran’s willingness to talk to the US  تلویزیون سفیر
    4. Exclusive: Details emerge of secret diplomatic efforts to restart Iran talks  CNN
    5. Israel Threatens Iran: ‘Return The Enriched Uranium, Or Else…’  Zee News

    Continue Reading

  • UAE Dirham moves up against Pak rupee – 5 July 2025

    UAE Dirham moves up against Pak rupee – 5 July 2025

    KARACHI – The buying rate of UAE Dirham (AED) recorded upward trend and now stood at Rs77.31 against Pakistani rupee in open market on Saturday.

    Similarly, the selling rate of the Dirham also increased and stood at Rs77 91, according to the forex.pk.

    AED to PKR Rate Today

    Buying Rs77.31

    Selling Rs77.91

    The UAE Dirham (AED) to Pakistani Rupee exchange rate holds great significance as millions of Pakistanis work in the UAE. Its stability ensures consistent remittance value, bolstering Pakistan’s foreign reserves and household incomes.Currency exchange helps determine the value of the Pakistani rupee against foreign currencies like the US dollar or UAE dirham. A strong exchange rate boosts imports and lowers inflation, while a weak rate can increase export competitiveness.

    It is also crucial for overseas Pakistanis who send remittances. Monitoring exchange rates helps businesses, travelers, and policymakers make informed financial decisions and manage economic stability effectively.

    Overseas Pakistanis residing in the UAE sent $754.2 million in wake of remittances in May 2025, securing second top position in the chart of the workers’ remittances as the first spot is held by Saudi Arabia.

    Meanwhile, the workers’ remittances from overseas to Pakistan, recording a significant growth of 28.8 percent during eleven months of fiscal year 2024-25, reached nearly $ 35 billion in the period from July to May while monthly inflows in May increased to $ 3.69 billion.

    “Cumulatively, with an inflow of US$ 34.9 billion, workers’ remittances increased by 28.8 percent during Jul-May FY25 compared to US$ 27.1 billion received during Jul-May FY24,” the State Bank of Pakistan reported on Wednesday.

    During May 2025, the workers’ remittances recorded an inflow of US$ 3.686 billion, depicting 16 percent growth over April 25 and 13.7 percent yearly increase against May 2024, the statistics showed.

    Continue Reading

  • Afghans both hopeful, disappointed after Russia's Taliban recognition – France 24

    1. Afghans both hopeful, disappointed after Russia’s Taliban recognition  France 24
    2. Russia becomes first state to recognise Afghanistan’s Taliban government  BBC
    3. Russia becomes first country to officially recognize Taliban government in Afghanistan  Ptv.com.pk
    4. Russia first country to recognise Afghan Taliban  Dawn
    5. Russia recognises the Taliban: Which other countries may follow?  Al Jazeera

    Continue Reading

  • How Jupiter’s growth spurt changed the paths of the planets

    How Jupiter’s growth spurt changed the paths of the planets

    Find out what Jupiter’s early days reveal about us in this one minute read

    • Jupiter was once a cosmic balloon: It used to be twice as big as it is now – that’s the equivalent of 8,000 Earths fitting inside it.
    • A powerful force: Its supercharged magnetic field was 50 times stronger, influencing the whole Solar System.
    • Why we’re here: Jupiter’s wild moves helped shape the paths of the planets – including Earth’s.
    • Clues from tiny moons: Scientists cracked this mystery by studying two of Jupiter’s smallest, oft-overlooked moons.
    • A window into our origins: Understanding Jupiter’s past helps explain how our own planet – and life – came to be.

    It’s astonishing that even after 4.5 billion years, enough clues remain to let us reconstruct Jupiter’s physical state at the dawn of its existence

    Fred C. Adams

    Continue Reading